We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+19.62%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$3B
AUM Growth
-$457M
Cap. Flow
-$118M
Cap. Flow %
-3.94%
Top 10 Hldgs %
45.74%
Holding
112
New
17
Increased
23
Reduced
25
Closed
15

Top Buys

Rank Stock Value
1
APGE icon
Apogee Therapeutics
APGE
+$40.3M
2
ARGX icon
argenx
ARGX
+$39.9M
3
RVMD icon
Revolution Medicines
RVMD
+$39.2M
4
IMVT icon
Immunovant
IMVT
+$29.2M
5
RYZB
RayzeBio, Inc. Common Stock
RYZB
+$16.3M

Top Sells

Rank Stock Value
1
RETA
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
+$68.3M
2
VIR icon
Vir Biotechnology
VIR
+$48M
3
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$46.2M
4
APLS
Apellis Pharmaceuticals
APLS
+$35.7M
5
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$33.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.21%
2 Financials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
26
Revolution Medicines
RVMD
$45.3B
$36.6M 1.22%
+1,321,795
New +$39.2M
SWTX
27
DELISTED
SpringWorks Therapeutics
SWTX
$35.2M 1.17%
1,520,416
-17,015
-1% -$465K
AXSM icon
28
Axsome Therapeutics
AXSM
$10.8B
$33.7M 1.12%
481,649
+210,156
+77% +$15.7M
HRMY icon
29
Harmony Biosciences
HRMY
$2.27B
$32.6M 1.09%
996,306
+104,936
+12% +$3.64M
RAPT
30
DELISTED
RAPT Therapeutics
RAPT
$31.9M 1.06%
240,082
-45,980
-16% -$7.51M
RCKT icon
31
Rocket Pharmaceuticals
RCKT
$415M
$31.1M 1.04%
1,517,467
+349,104
+30% +$6.35M
NAUT icon
32
Nautilus Biotechnolgy
NAUT
$112M
$28.8M 0.96%
9,111,151
– –
ACRV icon
33
Acrivon Therapeutics
ACRV
$93.4M
$28.8M 0.96%
3,007,858
– –
TNGX icon
34
Tango Therapeutics
TNGX
$4.18B
$27.2M 0.91%
+2,418,968
New +$14.8M
ADMA icon
35
ADMA Biologics
ADMA
$2.18B
$25M 0.83%
6,984,319
-4,915,936
-41% -$18.9M
TMCI icon
36
Treace Medical Concepts
TMCI
$313M
$24M 0.8%
1,834,060
-383,190
-17% -$7.01M
TARS icon
37
Tarsus Pharmaceuticals
TARS
$3.14B
$23M 0.77%
1,296,416
– –
COGT icon
38
Cogent Biosciences
COGT
$6.39B
$22.5M 0.75%
2,309,470
-350,000
-13% -$4.15M
SRPT icon
39
Sarepta Therapeutics
SRPT
$2B
$22.1M 0.74%
182,720
+101,646
+125% +$11.5M
MIRM icon
40
Mirum Pharmaceuticals
MIRM
$5.98B
$21.2M 0.71%
672,042
+70,476
+12% +$1.93M
OBIO icon
41
Orchestra BioMed
OBIO
$322M
$21.2M 0.71%
2,432,089
+379,221
+18% +$2.55M
XENE icon
42
Xenon Pharmaceuticals
XENE
$5.85B
$21.1M 0.7%
617,500
-605,877
-50% -$22.7M
VRCA icon
43
Verrica Pharmaceuticals
VRCA
$84.9M
$19.6M 0.65%
503,898
– –
BHVN icon
44
Biohaven
BHVN
$2.17B
$19.6M 0.65%
751,820
+431,000
+134% +$8.96M
MDGL icon
45
Madrigal Pharmaceuticals
MDGL
$11.8B
$18.2M 0.61%
124,637
-178,350
-59% -$33.6M
NBIX icon
46
Neurocrine Biosciences
NBIX
$15.6B
$17.9M 0.6%
159,242
+59,192
+59% +$6.23M
PTGX icon
47
Protagonist Therapeutics
PTGX
$9.74B
$17.6M 0.59%
1,054,273
-415,488
-28% -$8.06M
RYZB
48
DELISTED
RayzeBio, Inc. Common Stock
RYZB
$17.2M 0.58%
+776,805
New +$16.3M
CABA icon
49
Cabaletta Bio
CABA
$546M
$17.2M 0.58%
1,132,491
-412,509
-27% -$5.64M
RLAY icon
50
Relay Therapeutics
RLAY
$4.51B
$16.3M 0.55%
1,943,097
– –
1
2
3 4 5

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q3 2023 Portfolio in Review

As of Q3 2023, Perceptive Advisors held 112 positions worth $3B, down 13% from $3.45B the previous quarter. Its ten largest holdings account for 46% of the portfolio.

Perceptive Advisors withdrew a net $118M in Q3 2023, closing 15 positions and reducing 25 holdings. Its most notable exit was Reata Pharmaceuticals, Inc. Class A Common Stock, an estimated $68.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Perceptive Advisors opened a new position in Apogee Therapeutics worth $38.9M.

  • Perceptive Advisors's largest Q3 2023 buy was Apogee Therapeutics: 1,827,901 shares worth $38.9M.
  • Perceptive Advisors added most to argenx in Q3 2023, an estimated $39.9M increase.
  • Perceptive Advisors's biggest Q3 2023 reduction was Amylyx Pharmaceuticals, cutting an estimated $46.2M.
  • Perceptive Advisors fully exited Reata Pharmaceuticals, Inc. Class A Common Stock in Q3 2023, selling an estimated $68.3M.
  • Perceptive Advisors's ten largest holdings make up 46% of its $3B portfolio in Q3 2023.
  • Perceptive Advisors opened 17 new positions and closed 15 in Q3 2023.
  • Perceptive Advisors's portfolio value fell 13% quarter-over-quarter to $3B.

Based on Perceptive Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.